NCT07027111View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
DRUG

NVG-2089

Study drug

Trial Locations (1)

76208

RECRUITING

Nuvig Site, Denton

Sponsors
All Listed Sponsors
lead

Nuvig Therapeutics, Inc.

INDUSTRY

NCT07027111 - Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP | Biotech Hunter | Biotech Hunter